-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
Recently, GlaxoSmithKline (GSK) and Canadian biopharmaceutical company Medicago jointly announced that Health Canada has approved the new crown vaccine product Covifenz (plant-based virus-like particle [VLP], recombinant, adjuvant)
Covifenz is the first plant-derived new crown vaccine, and this approval marks the world's first regulatory approval for Covifenz
The Covifenz immunization schedule consisted of 2 intramuscular doses of the vaccine (3.
In December 2021, GSK and Medicago announced the results of the Covifenz global Phase 3 placebo-controlled vaccine efficacy study
The data showed that the overall vaccine efficacy of the Covifenz vaccine against all variants of SARS-COV-2 was 71% (95% CI: 58.
Reference source: Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine